Axsome Therapeutics Appoints John Golubieski as Chief Financial Officer
July 06 2017 - 7:00AM
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders, today
announced the appointment of John Golubieski as Chief Financial
Officer, effective August 4, 2017.
“John is an accomplished, results-oriented,
financial executive who has held leadership roles in large
multinational and specialty pharmaceutical companies,” said Herriot
Tabuteau, M.D., Chief Executive Officer of Axsome. “His financial
and accounting expertise, and significant transactional experience,
in both publicly-traded and private equity-backed companies, will
enhance Axsome’s organizational capabilities as we move towards our
goal of becoming a fully integrated biopharmaceutical company.”
Prior to joining Axsome, Mr. Golubieski was the
Chief Financial Officer of Osmotica Holdings, a commercial-stage,
private equity-backed pharmaceutical company. Previously, he was
the Chief Financial Officer of Fougera Pharmaceuticals, the former
U.S. business of Nycomed, until its acquisition
by Novartis for approximately $1.5 billion. Prior to Fougera
Pharmaceuticals, Mr. Golubieski was Senior Vice President,
Financial Planning & Analysis of King Pharmaceuticals
until its acquisition by Pfizer for approximately $3.6
billion. Prior to King Pharmaceuticals, he worked at Bristol-Myers
Squibb as Senior Director, Strategic Analysis in the Worldwide
Medicines Group where he was responsible for commercial valuation
of development compounds, and where he had financial oversight of
an operating division with $1.8 billion in annual sales. Mr.
Golubieski began his career at Price Waterhouse, where he served as
staff accountant. He earned his B.S. in Commerce and his M.B.A.
from Rider University.
“I am delighted to become part of the Axsome
management team at such an exciting time for the company,” said Mr.
Golubieski. “Axsome’s deep and growing late-stage clinical pipeline
for difficult-to-treat CNS disorders, worldwide product rights, and
registration strategies in both the U.S. and the E.U., provide the
potential for significant value creation. I look forward to
applying my skills and experience to support the realization of
this potential.”
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders for which
there are limited treatment options. Axsome’s product candidate
portfolio includes two late-stage candidates, AXS-05 and AXS-02.
AXS-05 is currently in a Phase 3 trial in treatment resistant
depression (TRD), and a Phase 2/3 trial in agitation in patients
with Alzheimer’s disease (AD) is planned. AXS-02 is currently in
Phase 3 trials in complex regional pain syndrome (CRPS) and knee
osteoarthritis (OA) associated with bone marrow lesions (BMLs) with
an additional Phase 3 trial planned in chronic low back pain (CLBP)
associated with Modic changes (MCs). AXS-05 and AXS-02 are
investigational drug products not approved by the FDA. For more
information, please visit the company website at www.axsome.com.
The company may occasionally disseminate material, nonpublic
information on the company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, interim
analyses and completion of the trials; the timing of and our
ability to obtain and maintain U.S. Food and Drug Administration or
other regulatory authority approval of, or other action with
respect to, our product candidates; the Company’s ability to
successfully defend its intellectual property or obtain the
necessary licenses at a cost acceptable to the Company, if at all;
the successful implementation of the Company’s research and
development programs and collaborations; the success of the
Company’s license agreements; the acceptance by the market of the
Company’s product candidates, if approved; and other factors,
including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein
could cause actual results and developments to be materially
different from those expressed in or implied by such statements.
The forward-looking statements are made only as of the date of this
press release and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstance.
Axsome Contact:
Mark Jacobson
Vice President, Operations
Axsome Therapeutics, Inc.
25 Broadway, 9th Floor
New York, NY 10004
Tel: 212-332-3243
Email: mjacobson@axsome.com
www.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2023 to Apr 2024